Minimally invasive procedures

Gerlag, Daniëlle M.; Tak, Paul P.

doi:10.1016/b978-0-323-06551-1.00031-2

Cited by 1 publication

(1 citation statement)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The blood vessels of the inflamed rheumatoid synovium tend to be straight branching in RA, as opposed to the tortuous pattern seen in spondyloarthritides 13 . It is known that the quantity of proinflammatory cytokines and inflammatory cells is reduced in the synovial membrane of treated RA patients with low disease activity 14 . Pretreatment synovial inflammation and tumor necrosis factor-α expression correlated with therapeutic response to infliximab 15,16 , and it has been shown that synovial cell infiltration, particularly by macrophages, and macrophage-derived cytokine expression were reduced after prednisolone therapy, with a significant correlation to beneficial clinical effect 17 .…”

Section: What Specifically Have We Learned From Analysis Of the Synov...mentioning

confidence: 99%

Synovial Tissue Analysis for the Discovery of Diagnostic and Prognostic Biomarkers in Patients with Early Arthritis: Table 1.

Hair

Harty²,

Gerlag

et al. 2011

J Rheumatol

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a chronic disease of unspecified etiology that is manifest by persistent inflammation of the synovium. Considerable efforts have been undertaken globally to study the microenvironment of the inflamed synovium, with many encouraging and enlightening results that bring us closer to unmasking the precise etiologies of RA. Subsequent to these efforts, it has been discovered that CD68-positive macrophages present in abundance in the synovial sublining of the inflamed synovium rescind with treatments that induce clinical improvement in RA. Examination of serial synovial biopsies is now commonly used for screening purposes during early drug development, and the number of centers able to perform synovial tissue biopsy sampling according to standardized methods is increasing. Having implemented the use of serial synovial tissue biopsies to evaluate the effects of new treatments on the group level in early proof of principle studies, it is the ambition of the OMERACT Synovial Tissue Group to identify synovial diagnostic and prognostic biomarkers that could be used in individual patients. Therefore, we started a prospective study termed the Synoviomics Project aimed at the identification of novel diagnostic and prognostic synovial biomarkers. We will use straightforward and powerful technologies to analyze patient material and assess clinical parameters to identify such biomarkers. These markers may be used in the future to identify patients who are at risk of having persistent and destructive disease and to start tailor-made targeted therapies in an early phase to prevent autonomous disease progression and irreversible joint damage.

show abstract